The Muscular Dystrophy Association Names Adam Cotumaccio as Executive Vice President, Chief Impact and Philanthropy Officer

NEW YORK, Sept. 27, 2018 /PRNewswire/ -- The Muscular Dystrophy Association (MDA) announced Adam Cotumaccio as executive vice president, chief impact and philanthropy officer, where he will lead the organization's strategic direction for all income generating activities.

Cotumaccio reports to Lynn O'Connor Vos, president and chief executive officer of the MDA, and sits on the executive leadership team.

With more than 20 years of diverse corporate executive management, start-up and non-profit experience, Cotumaccio oversees all donation and income generation and is responsible for developing and implementing new engagement activations for the company's strategic growth. He is spearheading donor engagement in his externally facing role, as well as overseeing all business development and corporate partnerships.

"Adam's diverse and extensive experience, as well as personal passion within the nonprofit world, made him the ideal candidate for our organization. I am confident that he will have a positive impact within our organization as a whole," said Lynn O'Connor Vos, president and chief executive officer of the MDA. "We look forward to having Adam continue to drive results and contribute to our mission of transforming the lives of people affected by neuromuscular disease through innovations in science and care."

Prior to joining the MDA, Cotumaccio was president and chief executive officer of Spence-Chapin Services to Families & Children, one of the oldest adoption and family services nonprofits in the U.S. He directed the work to transform the more than 100-year-old nonprofit.

His foray into the non-profit sector began in 1999, when he left Deloitte Consulting's Retail practice to co-found The Leverage Group; an entertainment, sports and cause marketing consultancy. Cotumaccio sold the company in 2008 to GroupM, the world's leading media investment/content management group. Throughout his 11 years there, he worked across various industries, developing award-winning partnerships for the company and working extensively with nonprofit organizations such as St. Jude Children's Research Hospital. Cotumaccio has also served on several nonprofit and for-profit boards and has extensive business development, fundraising, operations improvement and marketing experience. 

"The Muscular Dystrophy Association has a strong legacy and has made great strides in research to provide treatments for neuromuscular diseases. The role of fundraising and developing new income streams is critical to continuing the advancement of science and care," Cotumaccio said. "I look forward to working with the team to continue championing our cause and creating greater awareness for the work that we do."

About the Muscular Dystrophy Association
The Muscular Dystrophy Association is committed to transforming the lives of people affected by muscular dystrophy, ALS and related neuromuscular diseases. We do this through innovations in science and innovations in care. As the largest source of funding for neuromuscular disease research outside of the federal government, MDA has committed more than $1 billion since our inception to accelerate the discovery of therapies and cures. Research we have supported is directly linked to approved, life-changing therapies across multiple neuromuscular diseases. We support the largest network of multidisciplinary clinics providing best in class care at more than 150 of the nation's top medical institutions, and each year thousands of children and young adults learn vital life skills and gain independence at summer camp and through recreational programs, at no cost to families. For more information visit mda.org.

SOURCE Muscular Dystrophy Association

Related Links

http://www.mdausa.org